Contraline

Executive Summary

Contraline is a private clinical-stage medical device company developing novel reversible male contraceptives, including a topical gel and a long-acting implant. Founded in 2015 and headquartered in Charlottesville, Virginia, the company aims to provide men with convenient, effective, and reversible contraception options. Its lead programs target a significant unmet need in family planning, with the global male contraceptive market expected to grow as new options emerge. Contraline's products are designed to be non-hormonal and easily reversible, potentially offering a safer alternative to female contraceptives. The company has not yet disclosed funding details or valuation, but its innovative approach and focus on male contraception position it as a pioneering player in the space. Key near-term milestones include clinical trial progression for both product candidates, which could unlock additional financing and partnership opportunities. However, as a private early-stage company, Contraline faces regulatory and commercial risks typical of medical device development.

Upcoming Catalysts (preview)

• Q4 2026Topical gel Phase 2 clinical data readout65% success
• Q2 2027Long-acting implant first-in-human trial initiation50% success
• Q3 2026Strategic partnership or licensing deal for commercialization40% success